Attached files

file filename
EX-99.1 - EX-99.1 - Trius Therapeutics Incd544225dex991.htm
EX-99.2 - EX-99.2 - Trius Therapeutics Incd544225dex992.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 21, 2013

 

 

TRIUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-34828   20-1320630

(State of incorporation

or organization)

 

(Commission

file number)

 

(I.R.S. Employer

Identification Number)

 

6310 Nancy Ridge Drive, Suite 105

San Diego, CA

  92121
(Address of principal executive offices)   (Zip code)

Registrant’s telephone number, including area code: (858) 452-0370

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 21, 2013, our 2010 Equity Incentive Plan (the “2010 Plan”) was amended to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the 2010 Plan by 5,100,000 shares.

The foregoing description of the amendment to the 2010 Plan does not purport to be complete and is qualified in its entirety by reference to the 2010 Plan, as amended, attached to this Current Report on Form 8-K as Exhibit 99.1.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

Our 2013 Annual Meeting of Stockholders was held on May 21, 2013. We had 47,869,291 shares of common stock outstanding and entitled to vote as of April 5, 2013, the record date for the Annual Meeting. At the Annual Meeting, 41,266,312 shares of common stock were present in person or represented by proxy for the five proposals specified below.

At the Annual Meeting, stockholders:

(1) elected Karin Eastham, Seth H. Z. Fischer, Theodore R. Schroeder and Jeffrey Stein, Ph.D. as Class III directors to hold office until the 2016 Annual Meeting of Stockholders;

(2) approved, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the Annual Meeting;

(3) indicated, on an advisory basis, that the preferred frequency of stockholder advisory votes on the compensation of our named executive officers is three years;

(4) approved an amendment to the 2010 Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the 2010 Plan by 5,100,000 shares; and

(5) ratified the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2013.

The following sets forth detailed information regarding the final results of the voting for the Annual Meeting:

Proposal 1. Election of Directors

 

Name

   Votes For      Votes Withheld      Broker Non-Votes  

Karin Eastham

     29,193,883         225,950         11,846,479   

Seth H. Z. Fischer

     29,213,769         206,064         11,846,479   

Theodore R. Schroeder

     28,951,526         468,307         11,846,479   

Jeffrey Stein, Ph.D.

     29,199,475         220,358         11,846,479   

Proposal 2. Advisory Vote on Executive Compensation

 

Votes For      Votes Against      Abstentions      Broker Non-Votes  
  27,391,616         1,782,410         245,807         11,846,479   

Proposal 3. Advisory Vote on the Frequency of an Advisory Vote on Executive Compensation

 

1 Year      2 Years      3 Years      Abstentions      Broker Non-Votes  
  12,252,893         234,489         16,867,247         65,204         11,846,479   

Consistent with the preference of our stockholders indicated by the voting results for Proposal 3, we have decided to include a stockholder advisory vote on the compensation of our named executive officers every three years until the next required vote on the frequency of such advisory votes.

Proposal 4. Approval of Amendment to 2010 Plan

 

Votes For      Votes Against      Abstentions      Broker Non-Votes  
  26,578,276         2,564,781         276,776         11,846,479   

Proposal 5. Ratification of the selection of Independent Registered Public Accounting Firm

 

Votes For      Votes Against      Abstentions      Broker Non-Votes  
  40,806,124         163,968         296,220         —     


Item 8.01 Other Events.

On May 21, 2013, our Amended and Restated 2010 Non-Employee Directors’ Stock Option Plan (the “2010 Directors’ Plan”) was amended to, among other things, eliminate the “evergreen” provision providing for automatic annual increases in the number of shares of common stock available for issuance under the 2010 Directors’ Plan after the increase in shares that takes effect on January 1, 2015.

The foregoing description of the amendment to the 2010 Directors’ Plan does not purport to be complete and is qualified in its entirety by reference to the 2010 Directors’ Plan, as amended, attached to this Current Report on Form 8-K as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.

  

Description

99.1    2010 Equity Incentive Plan, as amended.
99.2    Amended and Restated 2010 Non-Employee Directors’ Stock Option Plan, as amended.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Trius Therapeutics, Inc.
Dated: May 24, 2013   By:  

/s/    John P. Schmid        

  Name:   John P. Schmid
  Title:   Chief Financial Officer


INDEX TO EXHIBITS

 

Exhibit
No.

  

Description

99.1    2010 Equity Incentive Plan, as amended.
99.2    Amended and Restated 2010 Non-Employee Directors’ Stock Option Plan, as amended.